OGN Stock Chart & Stats
$225.00
$0.00(0.00%)
―
--
Day’s Range― - ―
52-Week Range$106.15 - $270.99
Previous CloseN/A
VolumeN/A
Average Volume (3M)3.00
Market Cap
$62.08B
Enterprise Value$9.03K
Total Cash (Recent Filing)$1.12B
Total Debt (Recent Filing)$8.57B
Price to Earnings (P/E)14.2
Beta-0.83
Next Earnings
Aug 11, 2026EPS Estimate
15.78Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.95
Shares Outstanding262,609,440
10 Day Avg. Volume0
30 Day Avg. Volume3
Financial Highlights & Ratios
PEG Ratio-0.13
Price to Book (P/B)2.47
Price to Sales (P/S)0.30
P/FCF Ratio3.46
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Strong Free Cash Flow GenerationOrganon’s recent TTM cash generation is a durable financial strength: ~$850M operating cash flow and ~$614M FCF with +52% FCF growth. This provides consistent internal funding for operations, R&D, dividends or de-leveraging, supporting strategic flexibility over the next several quarters.
Diversified Commercial PortfolioOrganon’s mix of women’s health, biosimilars and established brands spreads revenue risk across product types and geographies. That structural diversification supports steadier cash flows and market access resilience versus reliance on a single molecule, aiding stability through market cycles.
Pipeline/product Expansion Via Licenses And PartnershipsThe MIUDELLA license adds a differentiated contraceptive to Organon’s women’s health franchise with a long commercial runway starting late 2026. Combined with expanded Samsung Bioepis commercialization rights, these deals bolster sustainable revenue optionality and product lifecycle renewal over coming quarters.
Bears Say
Highly Leveraged Balance SheetOrganon’s elevated debt load is a persistent constraint on strategic flexibility. High leverage increases refinancing and interest-rate risk, limits capital allocation choices, and raises vulnerability to operational setbacks or integration costs, making durable de-leveraging a near-term priority.
Sharp Revenue Decline And Compressed Net MarginA material TTM revenue contraction and net margin compression to ~4% reflect sustained pressure on pricing, mix, or volume. This weakens earnings power, reduces retained cash for reinvestment, and could persist through forthcoming quarters absent durable market-share or pricing recoveries.
Exposure To Pricing, Reimbursement And Generics CompetitionOrganon’s reliance on off-patent brands and biosimilars leaves it exposed to tendering, aggressive pricing, and reimbursement changes. These structural industry pressures can steadily compress revenues and margins across markets, especially in established-product segments over the medium term.
Organon News
OGN FAQ
What was Organon & Co.’s price range in the past 12 months?
Organon & Co. lowest stock price was $106.15 and its highest was $270.99 in the past 12 months.
What is Organon & Co.’s market cap?
Organon & Co.’s market cap is $62.08B.
When is Organon & Co.’s upcoming earnings report date?
Organon & Co.’s upcoming earnings report date is Aug 11, 2026 which is in 16 days.
How were Organon & Co.’s earnings last quarter?
Organon & Co. released its earnings results on Apr 30, 2026. The company reported $12.431 earnings per share for the quarter, missing the consensus estimate of $14.515 by -$2.084.
Is Organon & Co. overvalued?
According to Wall Street analysts Organon & Co.’s price is currently Undervalued.
Does Organon & Co. pay dividends?
Organon & Co. does not currently pay dividends.
What is Organon & Co.’s EPS estimate?
Organon & Co.’s EPS estimate is 15.78.
How many shares outstanding does Organon & Co. have?
Organon & Co. has 262,609,440 shares outstanding.
What happened to Organon & Co.’s price movement after its last earnings report?
Organon & Co. reported an EPS of $12.431 in its last earnings report, missing expectations of $14.515. Following the earnings report the stock price went down -0.433%.
Which hedge fund is a major shareholder of Organon & Co.?
Currently, no hedge funds are holding shares in MX:OGN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Organon Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
MX:OGN Sentiment 70%
Sector Average 65%
Sector Average 65%
Insider Transactions
Bought Shares
Worth $6.2M over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
35.45%
12-Months-Change
Fundamentals
Return on Equity
0.65%
Trailing 12-Months
Asset Growth
-1.22%
Trailing 12-Months
Company Description
Organon & Co.
Organon & Co., a global pharmaceutical enterprise, is dedicated to developing and delivering a wide array of prescription therapies. Its women's health division features reproductive care products, encompassing birth control and fertility treatments, notably Nexplanon/Implanon, an extended-duration contraceptive. The company's biosimilars collection includes three immune-related medications (Brenzys, Renflexis, Hadlima) and two cancer therapies (Ontruzant, Aybintio). Additionally, Organon provides cardiovascular medications, such as cholesterol-reducing drugs (Zetia, Ezetrol, Vytorin, Inegy, Rosuzet, Zocor) and treatments for high blood pressure (Cozaar, Hyzaar). Their respiratory product line addresses asthma symptoms with brands like Singulair, Dulera, Zenhale, and Asmanex, and manages seasonal allergies through Singulair, Nasonex, Clarinex, and Aerius. Furthermore, their offerings extend to dermatological care (Diprosone, Elocon), bone strengthening (Fosamax), and non-narcotic pain relief (Arcoxia, Diprospan, Celestone). The portfolio also comprises Proscar for treating symptomatic benign prostatic hyperplasia and Propecia for combating male pattern hair loss. The company's products are primarily distributed to pharmaceutical wholesalers, retailers, medical facilities, government entities, and various managed healthcare organizations, including health maintenance organizations and pharmacy benefit managers. Organon & Co. was established in 2020 and is headquartered in Jersey City, New Jersey.